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Abstract
Viruses confront a seemingly dichotomous relationship with their host cells. They must overcome host defenses in order to complete their
infectious cycles and generate new viruses yet the host must remain healthy and hospitable for that to take place. Shortly after infection, the RIGI-like receptors (RLRs) within the cytoplasm of the infected cell recognize foreign motifs present in the pathogen. The host responds by activating
a signaling pathway that leads to activation of cellular transcription factors, including the NF-κB and interferon regulatory factor 3 (IRF3), that
are necessary for induction of the type 1 interferon genes. Many viruses subdue components of the host innate immune system to facilitate viral
replication. Viruses with single stranded RNA genomes that possess double stranded replication intermediates, 5’ triphosphates or 5’ diphosphates
along with other secondary recognition motifs including length express proteins that either hide their dsRNA from detection by RLRs, interact with
RIG-I directly, or interfere with components of the RIG-I pathway with the ultimate goal of evading innate immunity. In every case the end result
is that the host antiviral defense system is crippled and viral propagation can proceed. In this review we focus on the eight emerging viruses
most likely to cause major epidemics, including Arenaviruses, Bunyaviruses, Coronaviruses, Filoviruses and Paramyxoviruses, as identified by
the World Health Organization in 2016. Once fully understood, the mechanisms employed by viruses to evade host cell immunity may serve as
effective targets for a variety of antiviral agents.
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Introduction
Upon viral infection host pathogen recognition receptors, including
the Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs), detect the
presence of foreign motifs referred to as pathogen-associated molecular
patterns (PAMPs) and activate a signaling pathway that ultimately leads to
the induction and expression of the type 1 interferons (IFN). This newly
produced IFN establishes an antiviral state in surrounding cells that
prevents virus replication. Therefore, induction of IFN gene expression
and the activation of subsequent IFN signaling pathways is crucial to
the ability of a host cell to mount an innate immune response [1]. To
counteract these powerful antiviral responses many viruses have evolved
elegant, and often multi-pronged, mechanisms by which they evade the
innate immune response [2]. There has been a tremendous amount of
research done to understand how different viruses block induction of the
IFN gene by either preventing recognition by RLRs or suppressing the
signaling pathways they activate. One well-studied member of the RLR
family is the retinoic acid–inducible gene-1 (RIG-I). This cytoplasmic
receptor primarily detects 5′ppp-RNA molecules with short secondary
motifs of dsRNA or ssRNA [3,4]. In contrast, another cytoplasmic RLR
referred to as MDA5 recognizes longer dsRNA motifs so that each
RLR recognizes different viruses based on their respective PAMPs [5].
Following binding of viral RNAs, RIG-I and MDA5 interact with the
mitochondrial membrane bound adaptor molecule MAVS (mitochondrial
antiviral signaling protein, also referred to as IPS-1, VISA, or CARDIF),
which activates two kinase complexes. The IκBKinaseɛ/ TANK Binding
Kinase 1 (IKKɛ/TBK1) phosphorylate the transcription factors, interferon
regulatory factors (IRF), IRF3 and IRF7, which then form homodimers
or heterodimers, enter the nucleus and initiate transcription of IFNα/β.
For clarity, it is worth mentioning that the type I interferons include a

subgroup of interferon proteins that include IFNα/β. While IRF3 is
constitutively expressed in most cells, IRF7 is an interferon stimulated
gene (ISG) that is typically expressed at low levels but can be induced
several-fold in response to IFN signaling. Therefore, it is thought that
IRF3 mediates transcription of the majority of early IFN expression. The
IKKα/IKKβ/IKKγ kinase complex phosphorylates IκBα, targeting this
repressor protein of nuclear factor kappa B (NF-κB) for degradation.
Following secretion outside of the initially infected cell, the IFN protein is
recognized by target cells and initiates their IFN signaling pathways [1,6].
Ultimately this leads to the expression or upregulation of hundreds of
ISGs, including IFN, pro-apoptotic factors, and cytokines which establish
an antiviral state in surrounding cells [1,7].
This review will focus on how select RNA viruses evade the innate
immune response. Specifically, we will focus on how the top eight emerging
viruses, as identified by the World Health Organization [8], suppress RIGI-mediated induction of the IFN antiviral response as shown in Figure 1.
In order to provide perspective, we also include information about how
vesicular stomatitis virus (VSV), a well-studied non-human pathogen,
evades the host immune response. VSV serves as a model for how nonhuman pathogenic RNA viruses act in manners both similar to and
different from the other emerging viruses. Taken together, the diversity of
mechanisms employed by these pathogens to circumvent host defenses is
remarkable. The similarities as well as the differences are striking.

Rift Valley Fever Virus and Crimean-Congo Hemorrhagic
Fever Virus
Members of the Bunyaviridae family that are listed in the 2016 WHO
list of emerging viruses include the zoonotic arthropod-borne Rift Valley
fever virus (RVFV) and the Crimean-Congo fever virus (CCHFV). Both
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transcription factor that regulates IFN-β gene expression [18]. YY1 directs
the SAP30-NSs-YY1 complex to the IFN- β promoter site to form a multi
protein repression complex on the promoter, which inhibits induction of
the IFN-β gene [17]. RVFV NSs also indirectly down regulates IFN-β gene
expression by shutting-off global host gene transcription by sequestering
the p44 and XPD subunits of the TFIIH basal transcription factor
[19]. NSs also inhibits host transcription by promoting the degradation of
the TFIIH p62 subunit [20].
Similarly, IFN production and secretion is delayed during CCHFV
infection [21,22]. A virally encoded protease processes the CCHFV
genome to include a 5′ monophosphate (5′p) end [23], rather than the
5′ppp and 5′pp ends strongly recognized by RIG-I [24]. Therefore it
was proposed that due to this modification CCHFV RNA is not sensed
by RIG-I [23,25]. However, recently it was established that RIG-I does
mediate an IFN response to CCHFV [26]. In fact, immuno stimulatory
RNA (isRNA) was isolated from infected cells as well as from virion
preparations, and RIG-I co-immuno precipitation resulted in the isolation
of CCHFV isRNA from infected cell lysates. These findings indicate that
RIG-I signaling is critical to the activation of an antiviral response to
CCHFV infection [26].

Figure 1: Targeting of the RIG-I signaling pathway by emerging virusesUpon activation by cytoplasmic RNA, RIG-I is activated and interacts
with MAVS. This initiates downstream signaling events that activate
IRF3 and NF-κB, and ultimately results in induction of the IFNα/β
gene. Many components in this pathway are inhibited by viral proteins,
thereby suppressing the IFN response and enabling viral replication to
occur. Viruses depicted above include Rift Valley fever virus (RVFV),
Crimean-Congo hemorrhagic fever virus (CCHFV), ebolavirus (EBOV),
Marburgh virus (MARV), Lassa fever virus (LASFV), Nipah virus (NiV),
severe acute respiratory syndrome coronavirus (SARS-CoV), Middle
East respiratory syndrome virus coronavirus (MERS-CoV) and vesicular
stomatitis virus (VSV).

of these viruses carry a tripartite negative sense RNA genome [9] and can
cause severe disease in humans, including fulminating hemorrhagic fever
[10,11].There are currently no prophylactic or therapeutic treatments
available for these viruses [9]. The pathogenicity of these viruses is largely
attributed to the ability of the multifunctional nonstructural protein NSs
to inhibit global host cell transcription and to antagonize the IFN system
[9,12-14].
Although RIG-I is activated upon recognition of RVFV RNA [15], IFN
production is delayed in RVFV-infected animal models [13]. Several studies
have demonstrated that the NSs protein utilizes several mechanisms to
block IFN-β gene expression during early RVFV infection [13,16,17]. NSs
was found to directly target IFN- β gene expression through its interaction
with the cellular repressor protein Sin3A-associated protein 30 (SAP30),
a subunit of the Sin3A/nuclear receptor co-repressor (NCoR)/histone
deacetylase repressor complex. NSs simultaneously interacts with YY1, a

While the CCHFV protein that antagonizes RIG-I-dependent IFN
production has not yet been identified, the viral L protein has been
suggested as a potential candidate. In addition to functioning as the
viral RNA dependent-RNA polymerase, the CCHFV L protein is a
cysteine protease that contains a viral homologue to the ovarian tumor
protease domain (OTU) [27], which allows the removal of conjugated
poly-ubiquitin (Ub) and interferon-induced Ub-like protein (ISG15)
from target proteins [28,29]. Viral proteases which contain this domain
evade ubiquitin- and ISG15-dependent innate immune responses [27,30],
therefore it is possible that the CCHFV OTU directly antagonizes the
innate immune response. More research must be done to determine if the
CCHFV OTU blocks RIG-I signaling and to identify which proteins in
the RIG-I pathway are targeted for OTU-dependent de-conjugation of Ub
and ISG15.

Ebola and Marburg Viruses
Ebolavirus (EBOV) and Marburg virus (MARV) are members of the
Filoviridae family that infect primates. They can cause hemorrhagic fever
and are among the most virulent pathogens known, with case fatality
rates reaching 90% during some outbreaks [31]. Mortality is swift and
follows the shock and subsequent multi-organ failure that results from
hemorrhagic complications [32]. This virulence is attributed to virally
encoded proteins that antagonize the ability of the host to mount
an effective innate immune response, leading to uncontrolled virus
replication. It has been demonstrated that EBOV VP24 and the MARV
VP40 inhibit the IFN signaling pathway [33,34]. As this occurs during
the later phase of the IFN response it will not be discussed further herein.
In addition to its function as a polymerase cofactor and its role in
viral assembly, the EBOV VP35 (eVP35) and MARV VP35 (mVP35)
suppress innate immunity by targeting multiple steps in the RIG-Idependent induction of IFN gene expression [35,36]. Both eVP35 and
mVP35 bind dsRNA [37] through a basic amino acid motif located in the
highly conserved C-terminal IFN-inhibitory domain (IID). This binding
sequesters the dsRNA from RIG-I surveillance and therefore prevents
IFN production. The IID domain interacts with dsRNA in a sequencespecific manner and was demonstrated to be essential for VP35-mediated
inhibition of IFN production [38-41]. By binding to viral dsRNA,
eVP35 inhibited activation of the IFN-β promoter normally induced
by overexpression of RIG-I, MAVS, IKKε and TBK1 [37]. Mutation of
dsRNA-binding residues led to a decrease in dsRNA binding [37,42].
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Comparison of the crystal structures of eVP35 and mVP35 IIDs bound
to dsRNA revealed that eVP35 interacts with both the phosphodiester
backbone and caps the ends of dsRNA [40,43], while mVP35 was found
to interact with the dsRNA backbone only [41]. Edwards and coworkers
established that eVP35 was able to more strongly inhibit RLR signaling
than mVP35. This correlated with induction of a more robust IFN
response in MARV-infected cells as compared to EBOV-infected cells.
These functional differences between eVP35 and mVP35 mapped to IID.
Therefore the binding mode of both viral VP35s with dsRNA plays a
significant role in the magnitude of the IFN response in filoviral-infected
cells [44].
While VP35 has been shown to bind synthetic dsRNA molecules
introduced in vitro [45], direct evidence that VP35 binds isRNA to limit
RIG-I activation was lacking. Utilizing a Sendai virus (SeV) infection
model and deep sequencing of purified eVP35-bound RNAs, Dilley and
coworkers demonstrated that the SeV defective interfering (DI) RNA,
a known activator of RIG-I, is the is RNA bound by eVP35 proteins in
infected cells. Mutation of basic residues in the IID domain that were
required for dsRNA binding and inhibition of IFN destroyed the ability
of eVP35 to bind the SeV DI RNA. In addition, select host RNAs were
preferentially bound by wild type eVP35 in cell culture. These findings
support the contention that VP35 binds viral isRNA to block the RIG-I
pathway and thereby evade the IFN response [45]. VP35 also inhibits
IFN production by targeting the RLR pathways in a dsRNA bindingindependent manner by interacting with key components of the RIG-I
pathway.
The IID was critical for the ability of eVP35 and mVP35 to block IRF3
phosphorylation and activation by over expression of IKKɛ and TBK1,
the kinases that activate this transcription factor [38,46]. In contrast,
these viral proteins did not inhibit IFN-β promoter activation induced by
expression of a constitutively active form of IRF3 [41,47]. Interestingly,
eVP35 was found to target and bind to the N-terminal domain of both
IKKɛ and TBK1 and was subsequently phosphorylated by these kinases.
Overexpression of eVP35 and its interaction with IKKɛ and TBK1,
sequesters them and impairs their normal interactions with IRF3, IRF7,
and MAVS, and decreases the kinase activity in cells transfected with
IKKɛ [47]. Taken together, these findings indicate that VP35 can act as
a decoy substrate for the TBK1-IKKε complex, thereby impairing IRF3
phosphorylation through its normal interaction with TBK1 and IKKɛ
[37,47].
Expression of wild-type eVP35 also interferes with the ability of RIG-I
to interact with PACT, a cellular dsRNA binding protein that is an essential
coactivator of RIG-I [48]. Mutations in the eVP35 IID domain prevented
eVP35-PACT binding and limited the ability of eVP35 to inhibit PACTmediated activation of RIG-I. Cells in which PACT had been knocked
down were defective for IFN induction and were insensitive to eVP35
activity [49].
It has been shown that TLR and RIG-I signaling covalently conjugates
SUMO molecules to both IRF3 and IRF7 and this modification was
correlated with reduced IFN transcription [50]. In addition, physical
interaction of eVP35 with IRF3 and IRF7 led to their sumoylation. This
modification inhibited the transcriptional activity of these IRFs and the
downstream expression from the IFN-β promoter [51].

Lassa Fever Virus
Like other members of the Arenaviridae family, Lassa fever virus
(LASFV) is an enveloped negative-sense RNA virus that carries a bisegmented genome [52]. LASFV is endemic in several West African
countries where there are between 300,000-500,000 cases annually.

Open Access
This virus can cause fatal hemorrhagic fever in humans, resulting in
approximately 5,000 deaths per year [53-56]. The pathogenesis of LASFV
is associated with the ability of this virus to specifically target dendritic
and endothelial cells [57,58]. In addition, LASFV is able to suppress the
induction of host IFNs.
While the 5′-ppp dsRNA associated with the LASFV genome activates
the RIG-I pathway [23], the virally encoded protein, NP, was identified
as an IFN antagonist [59-61]. By inhibiting IRF3 phosphorylation, the
multifunctional NP suppresses IFN induction [60,62]. This function of
the LASFV NP is dependent on its intrinsic 3′–5′ exoribonuclease (ExoN)
activity, which digests free dsRNA and thereby prevents RIG-I recognition
of that non-cellular nucleic acid [63,64]. Mutations in the exoribonuclease
active site dramatically reduced this activity and abrogated the ability of
the LASFV NP to inhibit viral- or synthetic polyI:C-induced activation of
the IFNα/β promoter in vitro [63-65]. Importantly, residues essential for
NP-mediated IFN inhibition are highly conserved among all arenaviruses,
indicating that this function too is conserved across all members of this
viral family [63,65,66]. A robust, RIG-I dependent, innate immune
response was activated in cells infected with a recombinant LASFV in
which the ExoN function was abolished. These results correlate with earlier
in vitro studies and underscore the essential role of the NP exonuclease
activity in suppression of innate immunity during LASFV infection [67].
This same region within the NP protein was found to antagonize
induction of IFN gene expression by inhibiting the nuclear translocation
and transcriptional activity of NF-κB [68] and by blocking the autocatalytic
activity of IKKɛ. By binding to the kinase domain of IKKɛ, NP inhibited
the ability of the kinase to phosphorylate, and therefore activate IRF3. This
NP-IKKɛ interaction also prevented IKKɛ from interacting with MAVS,
thereby blocking the RIG-I pathway [69]. Interestingly, mutation of the
same NP residues that are critical for its 3′–5′ exoribonuclease activity
perturbed the interaction of NP with IKKɛ[69].

Nipah Virus
Nipah virus (NiV), also identified as an emerging virus, is a lethal
pathogen that causes death in up to 70% of infected humans [70]. This
virus infects both bats and humans but most likely originated in the former
[71]. While other paramyxoviruses, such as Hendra virus, also use bats as
a natural reservoir they do not all infect both bats and humans [72]. In
fact, Hendra virus and NiV may be the only two and they are both lethal
in humans [73]. One study suggested that bat to human transmission, and
therefore the risk of human infection, is increased in those individuals
who drink tree sap [71]. Other studies have elucidated the mechanisms
employed by NiV to evade host innate immune responses.
When Pteropus vampyrus bat kidney (PVK) cells are infected with the
related avian Newcastle disease virus (NDV), Glennon and coworkers
observed an increase in expression of the genes encoding IFN, the GMCSF and IL-2 inhibitory factor I (GIF-I) and MDA5, among others [74].
In contrast, when those same cells are infected with NiV these genes
are not upregulated, suggesting that NiV, perhaps uniquely, antagonizes
expression of these host genes to facilitate viral replication. Suppression
of IFN expression is most likely achieved by the viral accessory proteins
V, W and C [75]. Similar responses involving the viral C protein have
been observed in cells infected with measles virus [76]. In that system
the suppression is most likely achieved by a combined mechanism that
includes suppression of Janus Kinase 1 (jak1) phosphorylation and
associated effects of the viral C protein [77]. The diversity observed in the
ways different paramyxoviruses suppress host antiviral responses suggests
that not only are their biological differences interesting but potential
therapeutic approaches must be targeted to specific viral pathogens.
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Severe Acute Respiratory Syndrome and Middle East
Respiratory Syndrome Viruses
The Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV)
was first identified in 2002 in China as the causative agent in those affected
individuals presenting with respiratory complications after exposure to a
single health care worker [78]. Within eleven weeks of the first incidence
in neighboring Hong Kong, the virus had spread to at least 27 countries
or distinct political entities with nearly one fourth of the reported cases
occurring among health care workers [79]. A wide range of fatality rates
have been reported and not surprisingly they vary by location and they
decrease over time [80,81]. The Middle East Respiratory Syndrome
coronavirus (MERS-CoV) is another highly pathogenic member of this
family. This lethal virus appears to be carried by Dromedary camels and is
transmitted directly from them to humans [82]. When discovered in 2012
the virus displayed a nearly 37% mortality rate [82].
Patients with severe SARS disease displayed dysregulated IFN, ISGs and
cytokine responses [83]. Similarly, MERS-CoV-infected cells exhibited
reduced IFN and cytokine expression, blocked IRF3-mediated induction
of the IFN response and upregulation of RIG-I, IRFs and other genes
associated with innate immunity [84-86]. Taken together, these findings
strongly suggest that the extreme virulence of SARS-CoV and MERSCoV is related to their ability to evade the host innate immune response.
SARS-CoV may hide its dsRNA from detection by RIG-I by replicating
in “inner vesicles” within the lumen of a virus-induced reticulo vesicular
network of modified endoplasmic reticulum (ER) membranes. The viral
replicase (composed of the nsp3, nsp5, and nsp8 proteins) as well as
the viral genomic RNA co-localize to these double membrane vesicles
(DMVs), providing evidence that SARS-CoV replicates in this membrane
network. The interior of these DMVs label for SARS-CoV dsRNA,
therefore this virus forms DMVs to coordinate its replication and also hide
replicating RNA from RLRs. The nsp4 viral replication protein appears to
direct this membrane rearrangement, as its mutation alters assembly of
these DMVs [87]. Interestingly, a similar phenomenon was observed in
MERS-CoV-infected cells [88], indicating that at least two coronaviruses
hide their dsRNA inside DMVs, avoiding detection by the host [89]. The
SARS-CoV nucleocapsid (N) protein may suppress IFN production via
a similar mechanism. Studies indicate that the N protein suppresses IFN
signaling by targeting an early step in the pathway [90,91] and binds to
dsRNA [51,92]. Therefore the N protein likely plays a key role in blocking
the innate immune response [91] by shielding dsRNA from recognition
by RIG-I. The SARS nsp14 protein contains a 3’-5’ exoribonuclease
domain, therefore this protein may function to limit the IFN response
by degrading viral dsRNA replication intermediates. Indirect support for
this notion comes from studies of the LASFV encoded NP which contains
a similar exonuclease domain. Mutation of critical residues within this
domain abrogated the ability of LASFV NP to inhibit induction of the
IFNα/β promoter [63-65]. While it is conceivable that the SARS-CoV
nsp14 protein suppresses the IFN response by degrading dsRNA, further
work is required to determine if this is indeed the case. Nevertheless, it is
interesting that similar approaches are employed by viruses from different
families. In this case an arenavirus and a coronavirus.
Several other proteins encoded by SARS-CoV antagonize the RIG-I
signaling pathway. For example, the ORF9b protein suppresses innate
immunity by targeting mitochondria and MAVS/TRAF3/TRAF6.
Expression of ORF9b altered the mitochondrial morphology and
subcellular localization of MAVS. The presence of ORF9b also led to the
ubiquitination and degradation of MAVS, accompanied by a loss of TRAF3
and TRAF6, two key components of the RIG-I signaling pathway [93]. The
SARS-CoV ORF3b and ORF6 proteins limit RLR-mediated induction
of IFN. ORF3 localized to the mitochondrial outer membrane and may

Open Access
therefore inhibit MAVS at the mitochondria or at a point downstream
of MAVS [90,94]. In contrast, ORF6 localized primarily to the ER and
Golgi apparatus and may disrupt the ER/Golgi transport necessary for
the IFN response [90]. The SARS-CoV M protein inhibits induction
of IFN by binding to TRAF3 and impeding the formation of a TRAF·TANK·TBK1/IKKɛ complex, thereby inhibiting TBK1/IKKɛ-dependent
activation of IRF3 and IRF7 [95]. Finally, the papain–like protease (PLP)
domain of the SARS-CoV nsp3 protein interacts with STING and disrupts
the dimerization and activation of this adaptor molecule. Inactive STING
is unable to recruit MAVS to the TBK1-IKKɛ complex, therefore these
kinases do not phosphorylate IRF3 and IFN gene expression is not
induced. The PLP domain of nsp3 also disrupts NF-κB signaling, possibly
by a similar mechanism [96] and it expresses a deubiquitinating activity
that removes Ub from key components of the pathway, including RIG-I,
STING, TBK1 and IRF3 [96,97].
Expression of the MERS-CoV ORF4b antagonizes the host IFNα/β
expression that is normally upregulated in response to viral infection
[98]. The accessory protein encoded by ORF4b, termed p4b, acts in both
the cytoplasm and the nucleus [99]. Interestingly, Yang and coworkers
demonstrated that in the cytoplasm p4b binds to TBK1 and IKKɛ, thereby
suppressing molecular interactions between MAVS and IKKɛ, while
inhibiting the phosphorylation of IRF3 [98]. When in the nucleus, the
same protein inhibits the IRF3 and IRF7 induced expression of IFN-β.
However, ablation of the protein’s nuclear localization signal eliminated its
ability to inhibit IFN- β expression but not the IFN- β expression induced
by RIG-I, TBK-1, MAVS, MDA5 and IKKɛ. This suggests that p4b
employs multiple approaches to inhibit IFN- β in both the cytoplasm and
the nucleus, no doubt contributing to the observed viral pathogenicity.
Interestingly, the MERS-CoV M protein is able to interact with TRAF3
which hampers the TRAF3-TBK1 interaction and therefore leads to a
decrease in IRF3 activation. The N-terminal transmembrane domain of
the MERS-CoV M protein is sufficient for interaction with TRAF3 [100],
which is similar to what has been shown for the SARS-CoV M protein
[101].

Vesicular Stomatitis Virus
While not on the WHO list of emerging viruses, VSV is a well-studied
member of the Rhabdoviridae with a host range that includes insects,
cattle, horses and pigs, and it serves as an excellent model system to study
the interplay between viruses and the IFN responses of their hosts. The
absence of IFN induction in wild type virus infected cells is thought to
result from the presence of one or more virally encoded IFN suppressors
that presumably are defective in IFN-inducing viruses [102]. One of these
suppressors is the matrix (M) protein which is crucial for many of the
cytotoxic effects associated with VSV infection, including the downregulation of global host gene expression [39,78,103] and inhibition of the
nuclear-cytoplasmic transport of host mRNAs [9,11,104]. The M protein
has been shown to inhibit host transcription [39,103] and suppress IFN-β
gene expression in the absence of other viral components [78]. Therefore,
several researchers have proposed that VSV evades the IFN response by
an M-mediated “shut-off ” of host gene expression. In support of this
hypothesis there is a strong correlation between the virus’s ability to
inhibit host gene expression and its ability to suppress IFN expression.
Wild type VSV rapidly inhibits host RNA and protein synthesis and is
a poor inducer, or non-inducer, of IFN [22]. In contrast, the VSV mutant
strain T1026R1 [103], which contains a single amino acid mutation at
position 51 (M51R) of the M protein [105], is delayed in its ability to
inhibit host RNA and protein synthesis [106] and is an excellent inducer
of IFN [21,30]. A recent study indicates that the M protein either in the
context of viral infection or when expressed alone is able to block viralmediated activation of NF-κB by targeting a step in the canonical NF-κB
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pathway, and the M51R mutation abrogates this function [107]. These
results imply that the VSV M protein encodes two suppressors of IFN
gene expression; the well-described ability to inhibit host gene expression
as well as the ability to suppress induction of the IFN-β promoter by
specifically interfering with the NF-κB pathway. This is similar to the
molecular strategies used by the RVFV NSs protein, which inhibits
IFN gene expression indirectly by inhibiting global host transcription
and directly by forming a multiprotein repression complex on the IFN
gene promoter.

Conclusion and Recommendation
Many of the emerging viruses discussed herein are lethal to humans.
While VSV is not lethal, it serves as a well-studied model of virus infection
and host immune detection and has revealed mechanisms of host innate
immune evasion that are seen in other viruses. Interestingly, even within
families of viruses the approaches used by the individual viruses to thwart
host innate immune surveillance vary. In contrast, some approaches are
shared among viruses of different families. Taken together, this tangled
story of host immune evasion by disparate RNA viruses makes the
prospect of using a single therapeutic approach impossible. Therefore it
is imperative that we better understand the specific interactions between
virally-encoded proteins and those of their hosts in order to develop lifesaving therapies.
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